Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

These are the RECONNECT studies, the paired Phase 3 randomized controlled trials that supported the June 2019 FDA approval of bremelanotide (Vyleesi) for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Investigators randomized 1,267 women across two parallel trials to subcutaneous bremelanotide 1.75 mg or placebo, administered on-demand approximately 45 minutes before anticipated sexual activity. Both trials used validated patient-reported outcome instruments to assess co-primary endpoints — change in sexual desire score and change in distress related to low desire — and both met both endpoints with statistical significance versus placebo. The most common adverse events were nausea (occurring in approximately 40% of bremelanotide-treated participants versus 1.3% on placebo), flushing, and headache; most events were mild-to-moderate and clustered in the first few doses, with no consistent escalation across treatment cycles. Transient hyperpigmentation and modest, time-limited blood-pressure increases were reported as known mechanism-derived effects of melanocortin agonism. The trial is the regulatory-grade evidence base that establishes bremelanotide's efficacy and safety profile for the FDA-labeled indication.

The labeled indication is narrow — premenopausal women with acquired generalized HSDD — and the trial population reflects that. Generalizability to postmenopausal women, men with erectile dysfunction or low libido, or individuals with HSDD secondary to specific medical or psychiatric conditions is not established by these trials. Patient-reported outcome measures for sexual desire are the regulatory-approved endpoint but are inherently subjective, and the placebo response in HSDD trials is generally substantial; the trials' use of validated PRO instruments and a placebo control adequately addresses these methodological concerns within the regulatory framework but should not be over-read. Industry sponsorship by Palatin Technologies and AMAG Pharmaceuticals (then Vyleesi's commercial partner) is disclosed; the primary endpoint is regulatory-grade and consistent with FDA review. Long-term safety beyond the trial period is addressed in label-required post-marketing surveillance rather than in this paper. The trial does not address chronic daily dosing — only the on-demand frequency that the FDA approved — so any biohacker use that exceeds the labeled cadence sits outside the evidence base reported here.